Abbott seeking approval for psoriasis mAb

Abbott Laboratories (NYSE:ABT) said it submitted regulatory applications last quarter in the U.S. and EU for briakinumab ( ABT-874; formerly J695) to treat moderate to severe psoriasis. The company also reported data on Tuesday from four Phase III trials showing that a significantly greater proportion of patients receiving briakinumab achieved skin clearance of 75%, as measured by Psoriasis Area and Severity Index (PASI), at week 12 vs. placebo, methotrexate or Enbrel etanercept. The mAb against IL-12 and IL-23 met the trials' primary endpoints. ...